{"company":{"id":3786085,"name":"Scala Biodesign","domain":"scala-bio.com","url":"https://alion.io/company/scala-bio"},"section":"news","answer":"Scala Biodesign: 10 headlines on record, 0 headlines in the last 90 days. Its story counts 2 milestones.","figures":[{"label":"Headlines","value":"10"},{"label":"In 90 days","value":"0"},{"label":"Milestones","value":"2"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":10},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":2}],"news":[{"date":"2026-04-02","kind":"News","title":"Scala Biodesign: $16 Million Raised For AI-Driven Protein Design Platform ScalaOS","source":"Pulse 2.0","url":"https://pulse2.com/scala-biodesign-16-million-raised-for-ai-driven-protein-design-platform-scalaos/"},{"date":"2026-03-31","kind":"News","title":"Scala Biodesign Raises $16M Series A Financing to Accelerate Development of Protein-Based Products with ScalaOS","source":"YahooFinance","url":"https://finance.yahoo.com/sectors/healthcare/articles/scala-biodesign-raises-16m-series-110000835.html"},{"date":"2025-11-02","kind":"Blog","title":"Stabilizing the malaria vaccine protein","url":"https://scala-bio.com/post/copy-of-stabilizing-the-malaria-vaccine-protein"},{"date":"2025-11-01","kind":"Blog","title":"Design of a challenging drug target","url":"https://scala-bio.com/post/design-of-a-challenging-drug-target"},{"date":"2025-10-31","kind":"Blog","title":"Stabilizing glucocerebrosidase (GCase) for Gaucher disease gene therapy","url":"https://scala-bio.com/post/stabilizing-glucocerebrosidase-for-gaucher-disease-gene-therapy"},{"date":"2025-10-30","kind":"Blog","title":"Simultaneous optimization of antibody developability & humanness","url":"https://scala-bio.com/post/simultaneous-optimization-of-antibody-developability-humanness"},{"date":"2025-10-29","kind":"Blog","title":"Improving catalytic activity and selectivity","url":"https://scala-bio.com/post/improving-catalytic-activity-and-selectivity"},{"date":"2025-10-28","kind":"Blog","title":"Co-optimizing stability and activity in a DNA processing enzyme","url":"https://scala-bio.com/post/co-optimizing-stability-and-activity-in-a-dna-processing-enzyme"},{"date":"2025-10-27","kind":"Blog","title":"Designing enzymes with complementary enantioselectivity profiles","url":"https://scala-bio.com/post/enantioselectivity-use-case"},{"date":"2025-10-26","kind":"Blog","title":"Enabling microbial production of a human enzyme","url":"https://scala-bio.com/post/enabling-microbial-production-of-a-human-enzyme"}],"story":[{"title":"Raised a round Series A $16M · YahooFinance","url":"https://finance.yahoo.com/sectors/healthcare/articles/scala-biodesign-raises-16m-series-110000835.html"},{"title":"Website went live first capture in the Wayback Machine","url":"https://web.archive.org/web/20211223195622/scala-bio.com"}],"as_of":"2026-11-16","cite":"Scala Biodesign, News. Alion, Nov 16, 2026. https://alion.io/company/scala-bio/news","html_url":"https://alion.io/company/scala-bio/news","json_url":"https://alion.io/company/scala-bio/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-16T00:49:49Z"}}